Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
Date:6/2/2008

var s=s_gi(s_account); var hd1 = document.getElementById('headline'); s.tl(this,'o',getLinkName('Company Sanpshot'));" >AEZS; TSX: AEZ) in the United States, Canada and Mexico.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for KRX-0401, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward- looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully c
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
2. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
3. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
4. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
5. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
6. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
7. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
8. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
9. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
10. Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
11. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 In response to urgent requests ... Sierra Leone , Direct Relief delivered two ... for the treatment of local health workers who contract Ebola ... dedicated Ebola care center was constructed for foreign health care ... not available for local Sierra Leonean health workers. ...
(Date:12/22/2014)... 2014 NxStage Medical, Inc. (NASDAQ: ... products, announced today that the U.S. Food and ... to perform hemodialysis overnight while the patient is ... NxStage,s® System One is the first and only ... indication. Home nocturnal hemodialysis is ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ... "Investment Analysis of the US Medical Device Sector ... http://photos.prnewswire.com/prnh/20130307/600769 This ... sector identifies the key trends and rationale for ... mergers and acquisitions. The study will ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2
... , PISCATAWAY, N.J., Dec. 1 ... of hearing instruments, announced its third annual partnership with Quota ... September 2010. , As part of the renewed partnership, Siemens ... hearing instruments to both children and young adults, age 23 ...
... , ... Board: CBPO) (Nasdaq: CBPO ) ("China Biologic," or,the "Company"), one ... Company has received approval to list its,common stock on the NASDAQ ... shares to begin trading on the NASDAQ on,Wednesday, December 2, 2009, ...
Cached Medicine Technology:Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 2Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 3China Biologic Products Approved to List on NASDAQ 2China Biologic Products Approved to List on NASDAQ 3
(Date:12/26/2014)... AZ (PRWEB) December 26, 2014 ... source for the best in heating, cooling and ... for 24 hour emergency services in 2014 with ... alike know that Arizona is known for its ... company that understands the intricacies and details of ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 ... Market Analysis to 2023” focuses on the current ... opportunities in the colorectal cancer market. Stivarga is ... of colon or rectal cancer. Boehringer Ingelheim is ... for the treatment of refractory CRC in the ...
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of wedding dresses ... selection of black one-shoulder cocktail dresses . In addition, ... available at discounted prices, up to 70% off. ... three weeks only. You know, we have thousands of frequent ... our new items can visit our website for more details. ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... sick children with complex chronic illnesses can receive effective, less ... home," with easy access to a team of dedicated health ... likely to become seriously ill and need either hospitalization or ... at an enhanced medical home clinic at the University of ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... Sunday, May 17, traffic near the University of Washington ... for the 27th annual Nordstrom Beat the Bridge to Beat ... Montlake Closures , From 7:30 a.m. until ... Street to 44th Avenue NE. 520 Ramp Closures ...
... 13 Helen Phillips may be the newest "Biggest Loser" ... achieving wellness. She knows "wellness" is about simple, everyday choices ... is like drinking wellness by the glass and is one ... joins the ranks of celebs and athletes to don a ...
... Speaker Nancy Pelosi received an "Award of Courage" ... future directions in the fight against HIV/AIDS. amfAR,s "Awards ... in recognition of the vision, determination, and courage that ... Other 2009 awardees are Senator Edward Kennedy, Dr. C. ...
... ,pill burden, has negative effects , , WEDNESDAY, May ... dialysis patients take, the more side effects they suffer ... study finds. , Dialysis patients have to take more ... this study, researchers at the Los Angeles Biomedical Research ...
... (CCHIT®) today announced that Glenwood System LLC’s ( http://www.GlenwoodSystems.com ) ... and meets the Certification Commission’s electronic health record (EHR) criteria ... and clinics where most Americans get their healthcare. , ... ...
... Inc. introduces KT Tape(TM) , the first-ever ... for consumer use. Kinesiology tape is a high performance ... muscle and joint injuries. Kinesiology tape has never been ... training to use it. Athletes no longer have to ...
Cached Medicine News:Health News:Nordstrom Beat the Bridge to Beat Diabetes Run to Temporarily Suspend Traffic in University District on Sunday, May 17 2Health News:Pelosi Remarks at amfAR Conference on Future Directions in Fight Against HIV/AIDS 2Health News:For Dialysis Patients, More Pills = Lower Quality of Life 2Health News:Glenwood System LLC'S GlaceEMR Receives 08 CCHIT Certification,Software Complies with Updated Interoperability Requirements 2Health News:Glenwood System LLC'S GlaceEMR Receives 08 CCHIT Certification,Software Complies with Updated Interoperability Requirements 3Health News:Glenwood System LLC'S GlaceEMR Receives 08 CCHIT Certification,Software Complies with Updated Interoperability Requirements 4Health News:KT Tape: Secret Weapon of Elite Athletes - Now Available to Everyone 2
... VersaPulse® PowerSuite™ holmium laser combines excellent ... precise, virtually bloodless procedures. It is ... and gall bladder stones of all ... surgical tool. Because its laser light ...
... The VersaPulse® PowerSuite™ holmium laser combines ... for precise, virtually bloodless procedures. It ... urinary and gall bladder stones of ... multipurpose surgical tool. Because its laser ...
Turnstile casting stand for easy and safe casting. The compact system sets up quickly and stores conveniently, and the non-stick coating prevents fiberglass or plaster from adhering to surface....
... features a unique self-contained delivery ... proven in Europe for more ... bone cement powder and liquid ... Cemex is designed to offer ...
Medicine Products: